CA2415793A1 - Methods of drug delivery to hepatocytes and treatment of flaviviridae infections - Google Patents

Methods of drug delivery to hepatocytes and treatment of flaviviridae infections Download PDF

Info

Publication number
CA2415793A1
CA2415793A1 CA002415793A CA2415793A CA2415793A1 CA 2415793 A1 CA2415793 A1 CA 2415793A1 CA 002415793 A CA002415793 A CA 002415793A CA 2415793 A CA2415793 A CA 2415793A CA 2415793 A1 CA2415793 A1 CA 2415793A1
Authority
CA
Canada
Prior art keywords
compound
hepatocyte
transporter
virus
carboxamidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002415793A
Other languages
English (en)
French (fr)
Inventor
Johnson Lau
Zhi Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Research and Development
Original Assignee
Ribapharm Inc.
Johnson Lau
Zhi Hong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc., Johnson Lau, Zhi Hong filed Critical Ribapharm Inc.
Publication of CA2415793A1 publication Critical patent/CA2415793A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002415793A 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections Abandoned CA2415793A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22686900P 2000-08-22 2000-08-22
US60/226,869 2000-08-22
US24062700P 2000-10-13 2000-10-13
US60/240,627 2000-10-13
PCT/US2001/026057 WO2002015904A1 (en) 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Publications (1)

Publication Number Publication Date
CA2415793A1 true CA2415793A1 (en) 2002-02-28

Family

ID=26920944

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002415793A Abandoned CA2415793A1 (en) 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Country Status (15)

Country Link
EP (1) EP1313469A1 (zh)
JP (1) JP2004506684A (zh)
KR (1) KR20030040416A (zh)
CN (1) CN1447692A (zh)
AU (1) AU2001292557A1 (zh)
BR (1) BR0113388A (zh)
CA (1) CA2415793A1 (zh)
CZ (1) CZ2003308A3 (zh)
HU (1) HUP0302884A2 (zh)
IL (1) IL154167A0 (zh)
MX (1) MXPA03001529A (zh)
NO (1) NO20030794L (zh)
PL (1) PL365744A1 (zh)
RU (1) RU2003102607A (zh)
WO (1) WO2002015904A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US20100112081A1 (en) 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) * 1993-05-26 1999-09-28 Laboratori Balducci S.P.A. Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO20030794L (no) 2003-04-22
WO2002015904B1 (en) 2002-07-04
JP2004506684A (ja) 2004-03-04
CN1447692A (zh) 2003-10-08
BR0113388A (pt) 2004-02-25
IL154167A0 (en) 2003-07-31
NO20030794D0 (no) 2003-02-20
CZ2003308A3 (cs) 2004-03-17
WO2002015904A1 (en) 2002-02-28
HUP0302884A2 (hu) 2003-12-29
AU2001292557A1 (en) 2002-03-04
EP1313469A1 (en) 2003-05-28
KR20030040416A (ko) 2003-05-22
PL365744A1 (en) 2005-01-10
MXPA03001529A (es) 2004-04-02
RU2003102607A (ru) 2004-07-27

Similar Documents

Publication Publication Date Title
CA2445744C (en) Antiviral nucleoside derivatives
US6495677B1 (en) Nucleoside compounds
US6455508B1 (en) Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
CN100528173C (zh) 4′-取代的核苷
US6815542B2 (en) Nucleoside compounds and uses thereof
US6423695B1 (en) Cytokine related treatments of disease
US6455690B1 (en) L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
AU2004216891A1 (en) Use of adenosine receptor agonists in therapy
CA2415793A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
AU732120B2 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US20040077563A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
US7056895B2 (en) Tirazole nucleoside analogs and methods for using same
US20090176721A1 (en) Nucleoside analogs with carboxamidine modified monocyclic base
Mirchandani et al. Drug delivery approaches for anti-HIV drugs
ZA200300649B (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections.
US7671038B1 (en) Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides
Curran et al. Clofarabine: in pediatric patients with acute lymphoblastic leukemia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued